Adverse effects of the antimalaria drug, mefloquine: Due to primary liverdamage with secondary thyroid involvement?

BMC Public Health

Volumn 2, Issue , 2002, Pages 1-8

  Croft, Ashley M ^a   Herxheimer, Andrew ^b  

^a MINISTRY OF DEFENCE   (United Kingdom)

^b UK COCHRANE CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; AMITRIPTYLINE; AMODIAQUINE; ANTIMALARIAL AGENT; CHLOROQUINE; CIPROFLOXACIN; DIAZEPAM; DIIODOHYDROXYQUIN; FLUPHENAZINE; ISOFLURANE; MEFLOQUINE; OFLOXACIN; ORAL CONTRACEPTIVE AGENT; PHENYLBUTAZONE; PRIMAQUINE; PROGUANIL; PSYCHOTROPIC AGENT; QUININE; SPARFLOXACIN; THIORIDAZINE; THYROXINE; VALPROIC ACID;

ABDOMINAL PAIN; ACUTE HEPATITIS; AMNESIA; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONVULSION; DEHYDRATION; DELIRIUM; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; ENDOCRINE DISEASE; FATTY LIVER; FEVER; HEADACHE; HEPATITIS; HUMAN; HYPOTHYROIDISM; LIVER CELL DAMAGE; LIVER DISEASE; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; MALAISE; MALARIA; MENTAL DISEASE; MULTICENTER STUDY; NAUSEA AND VOMITING; NONHUMAN; OCCUPATIONAL SAFETY; PARANOIA; PARASITOSIS; PHENOMENOLOGY; PREGNANCY; PRESCRIPTION; PSYCHOSIS; SEIZURE; SUICIDE ATTEMPT; THYROID DISEASE; ACUTE DISEASE; DRUG EFFECT; DRUG INTERACTION; LIVER CELL; PATHOLOGY; SAFETY; TOXIC HEPATITIS;

ACUTE DISEASE; ANTIMALARIALS; DRUG INTERACTIONS; HEPATITIS, TOXIC; HEPATOCYTES; HUMANS; LIVER DISEASES; MALARIA; MEFLOQUINE; SAFETY; THYROID DISEASES;

EID: 34248325649     PISSN: 14712458     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2458-2-6     Document Type: Article

References (79)

1. Tigertt WD: The army malaria research program. Ann Intern Med 1969, 70:150-3
2. Nosten F, van Vugt M: Neuropsychiatric adverse effects of mefloquine - what do we know and what should we do? CNS Drugs 1999, 11:1-8
3. Rønn AM, Rønne-Rasmussen J, Gøtzsche P, Bygbjerg IC: Neuropsychiatric manifestations after mefloquine therapy for Plasmodium falciparum malaria: comparing a retrospective and a prospective study. Trop Med Int Health 1998, 3:83-8
4. World Health Organisation: Review of central nervous system adverse events to the antimalarial drug mefloquine (1985-1990). Geneva: WHO, 1991. Report no: WHO/mal 91.1063.
5. Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD, Toovey S, Knobloch J, Nothdurft HD, Shaw D, et al: Atovaquone-proguanil versus mefloquine for malaria prophylaxis in non-immune travelers: results from a randomized double-blind study. Clin Infect Dis 2001, 33:1015-21
6. Bem L, Kerr L, Stuerchler D: Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 1992, 95:167-9
7. World Health Organisation: International Travel and Health. 2001
8. Schlagenhauf P: Mefloquine for malaria chemoprophylaxis 1992-1998: a review. J Travel Med 1999, 6:122-33
9. Toegenomen transpiratie met mefloquine (Lariam®). Geneesmiddelen Bulletin 1997, 31:97
10. Weinke T, Trautmann M, Held T, Weber G, Eichenlaub D, Fleischer K, Kern W, Pohle HD: Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 1991, 45:86-91
11. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ: Comparison of adverse events associated with use of mefloquine and combinations of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ 1996, 313:525-8
12. Huzly D, Schönfeld C, Beurle W, Bienzle U: Malaria chemoprophylaxis in German tourists: a prospective study on compliance and adverse reactions. J Travel Med 1996, 3:148-55
13. Phillips MA, Kass RB: User acceptability patterns for mefloquine and doxycycline malaria chemoprophylaxis. J Travel Med 1996, 3:40-5
14. Schlagenhauf P, Steffen R, Lobel H, Johnson R, Letz R, Tschopp A, Vranjes N, Bergqvist Y, Ericsson O, Hellgren U, et al: Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health 1996, 1:485-94
15. Handschin JC, Wall M, Steffen R, Stürchler D: Tolerability and effectiveness of malaria chemoprophylaxis with mefloquine or chloroquine with or without co-medication. J Travel Med 1997, 4: 121-7
16. van Riemsdijk MM, van der Klauw MM, van Heest JAC, Reedeker FR, Ligthelm RJ, Herings RMC, Stricker BHC, et al: Neuropsychiatric effects of antimalarials. Eur J Clin Pharmacol 1997, 52:1-6
17. Micheo C, Arias C, Rovira A: Adverse effects and compliance with mefloquine or chloroquine + proguanil malaria chemoprophylaxis. Proceedings of the Second European Conference on Travel Medicine; 2000 Mar 29-31; Venice, Italy. Venice: Fondazione Cini 2000
18. Kollaritsch H, Karbwang J, Wiedermann G, et al: Mefloquin- Konzentrationsprofile bei prophylaktischer Dosierung. Wien Klin Wochenschr 2000, 112:441-7
19. Wolters BA, Bosje T, Luinstra-Passchier MJ: Niet meer klachten bij mefloquinegebruik dan bij malariaprofylaxe met andere middelen. Ned Tijdschr Geneeskd 1996, 41:331-4
20. Smithuis FM, van Woensel JBM, Nordlander E, Vantha WS, ter Kuile FO: Comparison of two mefloquine regimens for treatment of lasmodium falciparum malaria on the northeastern Thai-Cambodian border. Antimicrob Agents Chemother 1993, 37:1977-81
21. Luxemburger C, Price RN, Nosten F, ter Kuile FO, Chongsuphajaisiddhi T, White NJ: Mefloquine in infants and young children. Ann Trop Paediatr 1996, 16:281-6
22. Mittelholzer ML, Wall M, Steffen R, Stürchler D: Malaria prophylaxis in different age groups. J Travel Med 1996, 4:219-23
23. ter Kuile FO, Nosten F, Thieren M, Luxemburger C, Edstein MD, Chongsuphajaisiddhi T, Phaipun L, Webster HK, White NJ: High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis 1992, 166:1393-400
24. Phillips-Howard P, ter Kuile FO: CNS adverse events associated with antimalarial agents. Drug Saf 1995, 12:370-83
25. Vanhauwere B, Maradit H, Kerr L: Post-marketing surveillance of prophylactic mefloquine (Lariam®) use in pregnancy. Am J Trop Med Hyg 1998, 58:17-21
26. Croft AMJ, Garner P: Mefloquine for preventing malaria in non-immune adult travellers (Cochrane Review). In: Cochrane Library. 2001
27. Finlayson NDC, Hayes PC, Simpson KJ: Diseases of the liver and biliary system. In: Haslett C, Chilvers ER, Hunter JAA, Boon NA, editors. Davidson's Principles and Practice of Medicine 1999, 683-736
28. Edwards CRW, Toft AD, Walker BR: Endocrine disease. In: Davidson's Principles and Practice of Medicine 1999, 543-98
29. Bangchang KN, Karbwang J, Back DJ: Mefloquine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochem Pharmacol, 1992, 43:1957-61
30. Gotsman I, Azaz-Livshits T, Fridlender Z, Muszkat M, Ben-Chetrit E: Mefloquine-induced acute hepatitis. Pharmacotherapy 2000, 20:1517-9
31. Jaspers CAJJ, Hopperus Buma APCC, van Thiel PPAM, van Hulst RA, Kager PA: Tolerance of mefloquine chemoprophylaxis in Dutch military personnel. Am J Trop Med Hyg 1996, 55:230-4
32. Takeshima S: Side effects with mefloquin for long-term malaria prophylaxis. Jpn J Trop Med Hyg 1994, 22:193-8
33. Reisinger EC, Horstmann RD, Dietrich M: Tolerance of mefloquine alone and in combination with sulfadoxine-pyrimethamine in the prophylaxis of malaria. Trans R Soc Trop Med Hyg 1989, 83:474-7
34. Neuberger J: Drugs and liver damage. In: Oxford Textbook of Medicine 1996, 2124-30
35. Grieco A, Vecchio FM, Natale L, Gasbarrini G: Acute fatty liver after malaria prophylaxis with mefloquine. Lancet 1999, 353:295-6
36. Wittes RC, Saginur R: Adverse reaction to mefloquine associated with ethanol ingestion. Can Med Assoc J 1995, 152:515-7
37. Vuurman EFPM, Muntjewerff ND, Uiterwijk MMC, van Veggel LMA, Crevoisier C, Haglund L, Kinzig M, O'Hanlon JF: Effects of mefloquine alone and with alcohol on psychomotor and driving performance. Eur J Clin Pharmacol 1996, 50:475-82
38. Meszaros K, Kasper S: Psychopathologische Phänomene im Langzeitverlauf einer akuten Psychose nach Mefloquin-prophylaxe (Lariam®). Nervenarzt 1996, 67:404-6
39. Gullahorn GM, Bohman HR, Wallace MR: Anaesthesia emergence delirium after mefloquine prophylaxis. Lancet 1993, 341:632
40. Castot A, Gamier R: Réflexion sur les effets secondaires de la méfloquine. Concours Med 1988, 110:4003
41. Conget JI, Navarro M, Navarro P, Corachán M: Alteración del perfil hormonal tiroideo tras la administración profiláctica de mefloquina. Med Clín (Barcelona) 1993, 100:516
42. Bauer WM, Craig CP: Acute psychotic reactions in an aid worker following separate administrations of mefloquine and iodoquinol. Proceedings of the Fifth International Conference on Travel Medicine; 1997 Mar 24-27; Geneva, Switzerland. Geneva: International Society of Travel Medicine, 1997
43. Nicolas X, Touze JE: La toxicité cardiaque des antipaludiques. Med Trop 1994, 54:361-5
44. Schmidt LH, Alexander S, Allen L, Rasco J: Comparison of the curative antimalarial activities and toxicities of primaquine and its d and l isomers. Antimicrob Agents Chemother 1977, 12:51-60
45. Neftel K, Woodtly W, Schmid M, Frick PG, Fehr J: Amodiaquine induced agranulocytosis and liver damage. BMJ 1986, 292:721-3
46. Larrey D, Castot A, Pessayre D, Merigot P, Machayekhy JP, Feldmann G, Lenoir A, Rueff B, Benhamou JP: Amodiaquine-induced hepatitis. A report of seven cases. Ann Intern Med 1986, 104:801-3
47. Woodtli W, Vonmoos P, Siegrist P, Zollikofer H: Amodiaquin-induzierte Hepatitis mit Leukopenie. Schweiz Med Wochenschr 1986, 116:966-8
48. Charmot G, Goujon C: Hépatites mineures pouvant êtres dues à l'amodiaquine. Bull Soc Pathol Exot 1987, 80:266-70
49. Bernuau J, Larrey D, Campillo B, Degott C, Verdier F, Rueff B, Pessayred D, Benhamou JP: Amodiaquine-induced fulminant hepatitis. J Hepatol 1988, 6:109-12
50. Raymond JM, Dumas F, Baldit C, Couzigou P, Beraud C, Amouretti M: Fatal acute hepatitis due to amodiaquine. J Clin Gastroenterol 1989, 11:602-3
51. Munera Y, Hughes FC, Le Jeunne C, Pays JF: Interaction of thyroxine sodium with antimalarial drugs. BMJ 1997, 314:1593
52. McGregor AM: The thyroid gland and disorders of thyroid function. In: Oxford Textbook of Medicine 1996, 1603-18
53. Barlow JW, Crowe TC, Topliss DJ: Thyroid hormone antagonism. In: Pharmacotherapeutics of the Thyroid Gland. 1997, 319-42
54. Stroev EA, Kochukov MY, Nikolaev VV: The lysosomal proteolytic system and functional activity of the rat thyroid in chloroquine administration. Eksp Klin Farmakol 1997, 60:50-2
55. Smith HR, Croft AM, Black MM: Dermatological adverse effects with the antimalarial drug mefloquine: a review of 74 published case reports. Clin Exp Derm 1999, 24:249-54
56. Ashby D, Smyth RL, Brown PJ: Statistical issues in pharmacoepidemiological case-control studies. Statist Med 1998, 17:1839-50
57. Boudreau E, Schuster B, Sanchez J, Novakowski W, Johnson R, Redmond D, Hanson R, Dausel L: Tolerability of prophylactic Lariam® regimens. Trop Med Parasitol 1993, 44:257-65
58. Petersen E: Malariaprofylakse. Virkninger og bivirkninger af farmaka der bruges til forebyggelse af malaria. Ugeskr Læger 1997, 159:2723-30
59. Olsen VV: Principielle overvejelser vedrørende malariaprofylakse. Ugeskr Læger 1998, 160:2410-1
60. Ragan E, Wilson R, Li F, Spasoff R, Bigelow G, Spinner N: Psychotic symptoms in volunteers serving overseas. Lancet 1985, ii:37
61. Potasman I, Berry A, Seligmann H: Neuropsychiatric problems in 2,500 long-term young travellers to the tropics. J Travel Med 2000, 7:5-9
62. Folkerts H, Kuhs H: Psychotische Episode infolge Malariaprophylaxe mit Mefloquin: eine kasuistische Mitteilung. Nervenarzt 1996, 63:300-2
63. Grupp D, Rauber A, Fröscher W: Neuropsychiatrische störungen nach malariaprophylaxe mit mefloquin. Akt Neurol 1994, 21:134-6
64. Rønn AM, Bygbjerg IC: Akut hjernesyndrom efter meflokinbehandling. Ugeskr Læger 1994, 156:6044-5
65. Hollweg M: Mefloquininduzierte Psychosen - Probleme der Kausalzuordnung anhand zweier kasuistischer Berichte. Psychiatr Prax 1995, 22:33-6
66. Heeringa M, Kuster JAM, Meyboom RHB, Bouvy M: Convulsies tijdens profylactisch gebruik van mefloquine. Ned Tijdschr Geneeskd 1998, 142:2477-80
67. Jensen JB, Meflochin: De neuropsykiatriske bivirkninger er ofte alvorlige og kan persistere længe efter ophør med medicinen. Ugeskr Læger 1998, 160:241
68. Bygberg IC, Rønn AM: Langvarige neuropsykiatriske bivirkninger efter meflochinprofylakse. Ugeskr Læger 1999, 161:1422-3
69. Fusetti M, Eibenstein A, Corridore V, Hueck S, Chiti-Batelli S: Meflochina ed ototossicità: descrizione di tre casi. Clin Ter 1999, 150:379-82
70. Lysack JT, Lysack CL, Kvern BL: A severe adverse reaction to mefloquine and chloroquine prophylaxis. Aust Fam Physician 1998, 27:1119-20
71. Van den Ende J, Coppens G, Verstraeten T, van Haegenborgh T, Depraetere K, van Gompel A, van den Enden E, Clerinx J, Colebunders R, Peetermans WE, et al: Recurrence of blackwater fever: triggering of relapses by different antimalarials. Trop Med Int Health 1998, 3:632-9
72. Durrheim DN, Gammon S, Waner S, Braack LEO: Antimalarial prophylaxis - use and adverse events in visitors to the Kruger National Park. S Afr Med J 1999, 89:170-5
73. Mangalvedhekar SS, Gogtay NJ, Wagh VR, et al: Convulsions in non-epileptics due to mefloquine-fluoroquinolone co-administration. Natl Med J India 2000, 13:47
74. Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A, McGready R, ter Kuile F, Looareesuwan S, White NJ: Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000, 356:297-302
75. Merritt JC: Mefloquine not first choice for aircrew. BMJ 1994, 308:721-2
76. Heno P: A propos de plongées et tropiques. Med Trop 2000, 60:103
77. Perry IC: Malaria prophylaxis. BMJ 1995, 310:1673
78. Botella de Maglia J, Casanovas AE: Acerca de la profllaxis del paludismo. Rev Clin Esp 1998, 199:549-50
79. Lobel HO, Miani M, Eng T, Bernard KW, Hightower AW, Campbell CC: Long-term prophylaxis with weekly mefloquine. Lancet 1993, 341:848-51